Skip to content

PHARMACENTRE: what changed

Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.

What changed

PHARMACENTRE

BE 0431.307.134
NACE 47.730, Retail sale of pharmaceutical products
fiscal year 2024 against 2025filed annual accounts (NBB)
Net result for the year
€56,429
2024 · €54,793+€1,636
Equity
€78,845
2024 · €77,417+€1,429
Cash
€37,902
2024 · €140,816-€102,913
Balance sheet total
€138,900
2024 · €141,827-€2,926

Largest movements

2024 to 2025
Assets
  • Cash -€102,913

    down €102,913 (-73.1%), from €140,816 to €37,902

    mainly Receivables within one year (-€99,987) and Contributions, distributions and other (-€55,000)

  • Receivables within one year +€99,987

    up €99,987 (+9890.3%), from €1,011 to €100,998

    of which Other amounts receivable: +€99,967

Equity and liabilities
  • Other debts -€5,000

    down €5,000 (-8.3%), from €60,000 to €55,000

  • Profit (loss) carried forward +€1,429

    up €1,429 (+15.5%), from €9,217 to €10,645

Income statement
  • Gross operating margin +€1,922

    up €1,922 (+2.6%), from €73,147 to €75,069

From the 2024 result to the 2025 result

effect on the result

Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.

Result 2024 €54,793
Gross operating margin +€1,922
Other operating charges +€13
Financial income -€32
Financial charges -€167
Taxes -€100
Result 2025 €56,429

Cash bridge derived

cash 2024 to 2025

Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.

From operations -€47,913
Investment €0
Financing -€55,000
Cash 2024 €140,816
Net result for the year +€56,429
Receivables within one year -€99,987
Tax, wage and social debts +€645
Other debts -€5,000
Contributions, distributions and other -€55,000
Cash 2025 €37,902
Every line side by side 33 lines
Line Code 2024 2025 Change %
Total assets 20/58 €141,827 €138,900 -€2,926 -2.1%
Current assets 29/58 €141,827 €138,900 -€2,926 -2.1%
Amounts receivable within one year 40/41 €1,011 €100,998 +€99,987 +9890.3%
Trade receivables 40 - €20 +€20
Other amounts receivable 41 €1,011 €100,978 +€99,967 +9888.3%
Cash at bank and in hand 54/58 €140,816 €37,902 -€102,913 -73.1%
Total equity and liabilities 10/49 €141,827 €138,900 -€2,926 -2.1%
Equity 10/15 €77,417 €78,845 +€1,429 +1.8%
Contributions 10/11 €62,000 €62,000 = 0.0%
Capital 10 €62,000 €62,000 = 0.0%
Issued capital 100 €62,000 €62,000 = 0.0%
Reserves 13 €6,200 €6,200 = 0.0%
Non-distributable reserves 130/1 €6,200 €6,200 = 0.0%
Legal reserve 130 €6,200 €6,200 = 0.0%
Profit (loss) carried forward 14 €9,217 €10,645 +€1,429 +15.5%
Amounts payable 17/49 €64,410 €60,055 -€4,355 -6.8%
Amounts payable within one year 42/48 €64,410 €60,055 -€4,355 -6.8%
Taxes, remuneration and social security 45 €4,410 €5,055 +€645 +14.6%
Taxes 450/3 €4,410 €5,055 +€645 +14.6%
Other amounts payable 47/48 €60,000 €55,000 -€5,000 -8.3%
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets 630 €0 - =
Other operating charges 640/8 €457 €445 -€13 -2.8%
Non-recurring operating charges 66A €0 - =
Gross operating margin 9900 €73,147 €75,069 +€1,922 +2.6%
Operating profit (loss) 9901 €72,690 €74,624 +€1,934 +2.7%
Financial income 75/76B €1,011 €979 -€32 -3.2%
Recurring financial income 75 €1,011 €979 -€32 -3.2%
Financial charges 65/66B €450 €617 +€167 +37.1%
Recurring financial charges 65 €450 €617 +€167 +37.1%
Profit (loss) for the period before taxes 9903 €73,251 €74,986 +€1,735 +2.4%
Income taxes 67/77 €18,458 €18,558 +€100 +0.5%
Profit (loss) for the period 9904 €54,793 €56,429 +€1,636 +3.0%
Profit (loss) for the period to be appropriated 9905 €54,793 €56,429 +€1,636 +3.0%

Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 30 September 2026 via checked.be.